Granulocyte-colony-stimulating-factor use in decompensated cirrhosis: lack of survival benefit and probable predisposition to hepatocellular carcinoma
ConclusionSurvival in DC was shorter than what was expected in the natural history of the disease after GCSF use.
Source: Journal of Clinical and Experimental Hepatology - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Children | Cirrhosis | Gastroenterology | Hepatocellular Carcinoma | History of Medicine | Jaundice | Liver | Liver Cancer | Liver Disease | Liver Transplant | Sodium | Study | Transplant Surgery | Transplants | Urology & Nephrology